Clinical Trial Update: Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating a combination of imatinib (Gleevec) and docetaxel (Taxotere) for advanced gastric adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• Gleevec (Imatinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Emory University | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: TERMINATED